Madrigal Pharmaceuticals, Inc. (MDGL)
NASDAQ · Healthcare
Madrigal Pharmaceuticals, Inc. Operating Income 2012–2025
Madrigal Pharmaceuticals, Inc. annual/quarterly operating income history and growth rate from 2012 to 2026. Operating income (EBIT) is profit from core business operations, excluding interest and income taxes. It reflects the efficiency of a company's core operations.
- Madrigal Pharmaceuticals, Inc. operating income for the quarter ending March 31, 2026 was -92.7 M, a 16.91% increase year-over-year.
- Madrigal Pharmaceuticals, Inc. operating income for the twelve months ending March 31, 2026 was -333.2 M, a 37.06% decrease year-over-year.
- Madrigal Pharmaceuticals, Inc. annual operating income for 2025 was -300.1 M, a 39.72% decrease from 2024.
- Madrigal Pharmaceuticals, Inc. annual operating income for 2024 was -497.9 M, a 30.85% increase from 2023.
- Madrigal Pharmaceuticals, Inc. annual operating income for 2023 was -380.5 M, a 29.61% increase from 2022.
- Madrigal Pharmaceuticals, Inc. annual operating income for 2022 was -293.6 M.
Operating Income
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Madrigal Pharmaceuticals, Inc. Operating Income — FAQ
Madrigal Pharmaceuticals, Inc. (MDGL) operating income over the last 10 years — annual and quarterly figures with year-over-year growth and charts.
What is Madrigal Pharmaceuticals, Inc.'s operating income?
Madrigal Pharmaceuticals, Inc. (MDGL) reported operating income of -$300M for fiscal 2025.
Where can I see MDGL's operating income history?
The chart and table above show Madrigal Pharmaceuticals, Inc.'s operating income by year and by quarter, including the growth rate.